Table 4. First hospitalization, multiple hospitalizations, and hospital days.
| All-Cause Hospitalization | Cardiovascular-Related Hospitalization | ||||||
|---|---|---|---|---|---|---|---|
| Sevelamer | Calcium | P | Sevelamer | Calcium | P | ||
| Hospitalized | 58.4% | 56.7% | 18.0% | 17.8% | |||
| First hospitalization | |||||||
| Mean patient-y of F/U | 0.83 | 0.80 | 0.83 | 0.80 | |||
| First hospitalization rate (/patient-y) | 0.70 | 0.71 | 0.22 | 0.22 | |||
| Unadjusted RR | 1.00 (0.98-1.03) | Reference | 0.8 | 0.98 (0.93-1.03) | Reference | 0.4 | |
| Multivariable-adjusted RR a | 0.99 (0.96-1.02) | Reference | 0.6 | 0.97 | 0.93-1.02 | Reference | 0.3 |
| PSM cohort RR b | 0.99 (0.97-1.02) | Reference | 0.7 | 0.98 | 0.93-1.03 | Reference | 0.4 |
| Multiple hospitalizations | |||||||
| Mean patient-y of F/U | 1.59 | 1.49 | 1.59 | 1.49 | |||
| Multiple hospitalization rate (/patient-y) | 1.29 | 1.28 | 0.39 | 0.39 | |||
| Unadjusted RR | 1.03 (0.99-1.06) | Reference | 0.07 | 1.02 | 0.98-1.07 | Reference | 0.3 |
| Multivariable adjusted RR a | 1.01 (0.99-1.04) | Reference | 0.4 | 1.01 | 0.97-1.05 | Reference | 0.6 |
| PSM cohort RR b | 1.00 (0.97-1.07) | Reference | 0.8 | 1.00 | 0.96-1.05 | Reference | 0.9 |
| Hospital days | |||||||
| Mean patient-y of F/U | 1.62 | 1.52 | 1.62 | 1.52 | |||
| Rate for hospital days (/patient-y) | 8.4 | 8.4 | 2.1 | 2.1 | |||
| Unadjusted RR | 1.01 (0.96-1.05) | Reference | 0.8 | 1.00 | 0.95-1.07 | Reference | 0.9 |
| Multivariable-adjusted RR a | 0.99 (0.95-1.03) | Reference | 0.5 | 0.99 | 0.93-1.05 | Reference | 0.6 |
| PSM cohort RR b | 0.98 (0.94-1.03) | Reference | 0.4 | 0.99 | 0.93-1.05 | Reference | 0.7 |
Values in parentheses are 95% confidence intervals.
PSM, propensity score-matched; F/U, follow-up; RR. relative risk
a
Adjusted for age; sex; race; ethnicity; cause of end-stage renal disease; dialysis vintage; hematocrit value; vascular access type; baseline treatment with erythropoiesis-stimulating agents, vitamin D, β blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/renin inhibitors, calcium channel blockers, statin, and cinacalcet; baseline hospitalizations; and baseline comorbid conditions.
b
Analysis was restricted to patients included in the PSM cohort.